Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 75Years
All Genders
NCT06456528

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2026-01-12

235

Participants Needed

2

Research Sites

110 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.

CONDITIONS

Official Title

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women, 18-75 years of age
  • Cancer confirmed by histopathological or cytological examination
  • Chemotherapy cycle of 21 days
  • Experienced thrombocytopenia and chemotherapy delay
  • ECOG performance status 0-1
  • Estimated survival time of at least 12 weeks at screening
  • Current chemotherapy regimen planned for at least 2 more cycles
Not Eligible

You will not qualify if you...

  • History of hematologic diseases other than chemotherapy-induced thrombocytopenia
  • Serious bleeding symptoms
  • Allergy to the study drug
  • Positive for hepatitis C antibody with high HCV-RNA levels
  • Positive for hepatitis B surface antigen with high HBV-DNA levels
  • Severe cirrhosis
  • Positive for HIV or syphilis antibodies
  • Pregnant or lactating women
  • Received any experimental therapy within 28 days before screening
  • Other conditions affecting safety or trial evaluations as decided by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Harbin First Hospital

Harbin, China

Actively Recruiting

2

Nanjing Tianyinshan Hospital

Nanjing, China

Actively Recruiting

Loading map...

Research Team

J

Jun Ma

CONTACT

S

Shukui Qin

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here